Springer Nature
Browse
40425_2019_680_MOESM4_ESM.pptx (189.54 kB)

Additional file 4: of A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Download (189.54 kB)
presentation
posted on 2019-07-26, 04:25 authored by Alexandra Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise Kohn, Christina Annunziata, Stanley Lipkowitz, Jane Trepel, Rajni Sharma, Lekha Mikkilineni, Margaret Gatti-Mays, William Figg, Nicole Houston, Jung-Min Lee
Figure S4. Proinflammatory cytokines analysis. Plasma levels of pro-inflammatory cytokines (IFN γ, TNFα, IL 2, IL 6, IL 8 IL 10, and IL 12) were not changed significantly by the treatment. (PPTX 189 kb)

Funding

National Cancer Institute, National Institutes of Health

History